Which cancers can I use ImpriMed for? or What type of cancer does ImpriMed predict?

Currently, our services are for canine lymphoma and leukemia. We will be expanding our services to other species and other blood / lymphoid cancers in the near future.

Other Questions

Back to Help Center

For the blood tube submission– Do you request that on every patient, even if they don't have a leukemic component? And what type of blood tube do you request we send the sample in?

We require at least 2 mL of whole blood in an EDTA-treated tube.

Why should I order ImpriMed services?

ImpriMed offers a unique precision oncology service that helps you to find the best anticancer drugs for your patients. ImpriMed directly tests a panel of commonly used anticancer drugs on your patients’ live cells in our A2LA accredited lab. In addition, we continually collect patient outcomes that are updated via regular follow-up with pet parents. As our database grows, so does the performance of our anticancer drug response predictions and your ability to develop a personalized treatment plan for each pet patient. So, when you order an ImpriMed service, you are actively contributing to our dataset and helping to improve cancer care for your patients and the ImpiMed user community.

Can the testing be performed on dogs that are currently on therapy?

Current therapy will not affect our AI predictions or immunoprofile results. However, reduction of tumor size caused by therapy may increase the likelihood of service failure due to insufficient cells. In the event of service failure, you will not be billed.

How can I help to advance precision medicine?

The more samples ImpriMed processes and the more clinical outcomes we receive from our customers, the more accurately our AI models are able to determine which drugs will work best for your patients. (Click to read more)

For patients who already have flow cytometry, can you just run the drug sensitivity profile?

No, we cannot run a drug sensitivity-only service. Please understand our AI-based drug response prediction models require flow cytometry and PARR parameters generated from our own instrumental setting. Even if the patient already has flow cytometry results from another laboratory, we need to run flow and PARR again anyway.